Modeling chromosome 7 loss in Myelodysplasia-iPSCs
Modeling chromosome 7 loss in Myelodysplasia-iPSCs
批准号:
8788296
负责人:
Eirini Papapetrou
金额:
$41.74万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2019-02-28
关键词:
Acute leukemiaAffectAnimal ModelApoptosisBiologicalBiological AssayBiological MarkersBone MarrowBone Marrow CellsCandidate Disease GeneCell CycleCell LineCell ProliferationCell physiologyCell surfaceCellsCellular biologyCharacteristicsChromosome abnormalityChromosomesChromosomes, Human, Pair 7DNA DamageDataDevelopmentDiseaseDysmyelopoietic SyndromesElementsEngineeringEtiologyGene TargetingGenesGeneticGenetic EngineeringGenomicsGoalsHealthHematopoiesisHematopoieticHeterogeneityHumanHuman GenomeIncidenceIneffective HematopoiesisInvestigationLeadLibrariesMediatingMethodologyMethodsModelingMolecularMolecular GeneticsMolecular and Cellular BiologyOpen Reading FramesPancytopeniaPathogenesisPathway interactionsPatientsPhenotypePluripotent Stem CellsPreleukemiaRecurrenceResourcesRoleSomatic CellStem Cell ResearchStratificationTechnologyTimeTissue SampleUndifferentiatedWorkarmbasebone marrow hyperplasiacellular engineeringchromosome 7 losschromosome 7q lossclinical decision-makingdisease mechanisms studyembryonic stem cellinduced pluripotent stem cellinsightleukemianew technologynoveloutcome forecastpalliativeresponsereverse geneticstargeted treatmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a propensity for progression to bone marrow (BM) failure or acute leukemia. Despite their relatively high incidence, very little is known about their pathogenesis and their treatment remains mainly palliative. This is largely due to the unavailability of good animal models and the challenges of the ex vivo culture of primary MDS cells. Loss of the entire or part of chromosome 7 [del(7/7q)] is a recurrent cytogenetic abnormality in MDS, associated with unfavorable prognosis, strongly suggesting that one or more critical genes - that so far remain elusive - reside in chromosome 7q. With recent breakthroughs in human pluripotent stem cell (hPSC) research - direct reprogramming and new genetic engineering technologies - reverse genetics in an isogenic setting by precise disruption of genomic elements into their cognate genomic and cellular context - hitherto unthinkable for the human genome - are now a realistic prospect. Our goal is to harness cutting-edge reprogramming and genetic engineering technologies that we and others have developed to establish a novel hPSC-based model to study the cellular, molecular and genetic pathogenesis of myelodysplasia. In preliminary studies, we have derived MDS-iPSC lines with chromosome 7q deletions from patient BM cells and found that they recapitulate potential disease- associated phenotypes: impaired cell proliferation and hematopoietic differentiation. In the proposed study we plan to derive additional del(7q)- as well as isogenic karyotypically normal iPSCs, through reprogramming and chromosome engineering, and characterize their phenotype in the undifferentiated state and following hematopoietic differentiation. To identify genes with a role in MDS pathogenesis, we will perform a screen of candidate genes residing in chromosome 7q for rescue of proliferation in our del(7q)- hPSCs. These studies, using powerful new technologies, will provide a novel valuable resource for the study of myelodysplasia, generate insights into the cellular processes and molecular pathways affected and potentially identify critical genes in the pathogenesis of MDS, bone marrow failure and preleukemia, in general.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms
-
批准号:10659809
-
项目类别:
-
资助金额:$67.09万
-
财政年份:2023
-
负责人:Eirini Papapetrou
-
依托单位:
Impact of mutational order on molecular mechanisms of oncogenesis
-
批准号:10375146
-
项目类别:
-
资助金额:$66.53万
-
财政年份:2022
-
负责人:Eirini Papapetrou
-
依托单位:
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations
-
批准号:10643995
-
项目类别:
-
资助金额:$65.84万
-
财政年份:2022
-
负责人:Eirini Papapetrou
-
依托单位:
Impact of mutational order on molecular mechanisms of oncogenesis
-
批准号:10620122
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2022
-
负责人:Eirini Papapetrou
-
依托单位:
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations
-
批准号:10450238
-
项目类别:
-
资助金额:$68.91万
-
财政年份:2022
-
负责人:Eirini Papapetrou
-
依托单位:
Dissecting splicing factor mutations in iPSCs
-
批准号:9893894
-
项目类别:
-
资助金额:$78.89万
-
财政年份:2017
-
负责人:Eirini Papapetrou
-
依托单位:
Dissecting splicing factor mutations in iPSCs
-
批准号:9317606
-
项目类别:
-
资助金额:$82.81万
-
财政年份:2017
-
负责人:Eirini Papapetrou
-
依托单位:
Modeling chromosome 7 loss in Myelodysplasia-iPSCs
-
批准号:9038428
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2014
-
负责人:Eirini Papapetrou
-
依托单位:
Modeling chromosome 7 loss in Myelodysplasia-iPSCs
-
批准号:9234586
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2014
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8955926
-
项目类别:
-
资助金额:$14.41万
-
财政年份:2012
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8573597
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8588316
-
项目类别:
-
资助金额:$11.77万
-
财政年份:2012
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8427703
-
项目类别:
-
资助金额:$4.21万
-
财政年份:2011
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8289614
-
项目类别:
-
资助金额:$9.0万
-
财政年份:2011
-
负责人:Eirini Papapetrou
-
依托单位:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
-
批准号:8110781
-
项目类别:
-
资助金额:$4.79万
-
财政年份:2011
-
负责人:Eirini Papapetrou
-
依托单位:
海外基金